Open AccessPrescription-Event monitoring study on safety and efficacy of levonadifloxacin (oral and I.V.) in management of bacterial infections: Findings of real-world observational study
Author(s) -
KapilDev Mehta,
Yatin Mehta,
AnandR Sutar,
Kapil Zirpe,
JayNarendra Kothari,
Chakravarthi Alapati,
Manu Pathak,
VasantC Nagvekar,
Khokan Debnath
Publication year - 2022
Publication title -
international journal of applied and basic medical research/international journal of applied and basic medical research
Language(s) - English
Resource type - Journals
eISSN - 2248-9606
pISSN - 2229-516X
DOI - 10.4103/ijabmr.ijabmr_602_21
Subject(s) - medicine , adverse effect , neutropenia , diarrhea , pneumonia , vomiting , nausea , staphylococcus aureus , bacterial pneumonia , chemotherapy , biology , bacteria , genetics
Levonadifloxacin is a novel broad-spectrum antibiotic belonging to the benzoquinolizine subclass of quinolones. It is available in intravenous as well as oral formulation for the treatment of infections caused by common Gram-positive bacterial pathogens including methicillin-resistant Staphylococcus aureus (MRSA).